Certain infectious diseases, such as COVID or the flu, evolve constantly, shapeshifting just enough to outmaneuver our immune ...
Recall germinal centers formed in response to a secondary infection generate a second line of defense, rebuffing memory B ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of ...
GlobalData on MSN6h
Recordati to acquire worldwide rights to Sanofi’s antibody EnjaymoRecordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment ...
News Medical on MSN4d
Discovery of antibodies that boost complement activation against K. pneumoniaeThe introduction of clustered enhancing mutations led to complement activation by anti-capsule antibodies for both K.
Research at UMC Utrecht has identified 29 novel antibodies against the bacterium Klebsiella pneumoniae, an important cause of ...
Research at UMC Utrecht has identified 29 novel antibodies against the bacterium Klebsiella pneumoniae, an important cause of ...
WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host ...
Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...
Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic ...
During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to ...
Merck completes acquisition of investigational B-cell depletion therapy, CN201 from Curon Biopharma: Rahway, New Jersey Thursday, October 3, 2024, 10:00 Hrs [IST] Merck, known as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback